Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning. Winston Churchill, address to Parliament, 10 November 1942 A key question is, can ...

Viral subunit vaccines often contain immunodominant non-neutralizing epitopes that divert host immune responses. These epitopes should be eliminated in vaccine design, but there is no reliable method ...

We discovered high-titer neutralizing autoantibodies against interleukin-10 in a child with infantile-onset inflammatory bowel disease (IBD), a phenocopy of inborn errors of interleukin-10 signaling.

Scientists at The Wistar Institute have developed an HIV vaccine candidate that achieves something never before observed in the field: inducing neutralizing antibodies against HIV after a single ...

Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern pose a challenge to the effectiveness of current vaccines. A vaccine that could prevent infection caused by ...

Caused by the worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the coronavirus disease 2019 (COVID-19) pandemic continues to damage global public health and economic ...

Infections with the hepatitis E virus often go unnoticed because they cause no symptoms. However, in patients with a weakened immune system or existing liver damage and also in pregnant women, the ...

It has been one year since the outbreak of COVID-19, but there is still an increasing number of confirmed cases. The epidemic situation is still challenged all over the world. The effective drug ...

Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533 Vaccine-induced nAbs are detectable at much lower rates ...

Scientists at the Jackson Laboratory (JAX) have developed an antibody-based therapy against influenza A virus (IAV), which they suggest could change the way the world fights flu, one of the deadliest ...

Antibodies have become an integral part of research and medicine. Therapeutic applications of antibodies began to emerge following the publication of Köhler and Milstein’s groundbreaking 1975 paper in ...

Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001). Background: Neoadjuvant ...